EGFR and central nervous system cancer: Depatuxizumab mafodotin (ABT-414), an EGFR-targeting antibody–drug conjugate [42], selectively killed tumor cells overexpressing wild-type or mutant forms of EGFR and reduced glioma growth in mice [43].